A Phase 1b, Open-Label, Dose-Escalation Trial of the Safety of and Antigen-Specific Immune Responses Elicited by VB.10 NEO in Combination With Atezolizumab in Subjects with Locally Advanced and Metastatic Tumors

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509996-18-00

Acronym

VB N-02

Enrollment

Registered

2024-04-04

Start date

2022-01-18

Completion date

2024-10-09

Last updated

2024-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anal, cervical, gastric/GEJ cancer, head and neck squamous cell carcinoma, Locally advanced and metastatic solid tumor including non-small cell lung carcinoma, or MSI-high tumors, renal cell carcinoma, triple-negative breast cancer, urothelial carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

Germany, Spain

Outcome results